NCT05398861View on ClinicalTrials.gov

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
HER-2 Negative Breast Cancer
Interventions
DRUG

Utidelone Combined with Bevacizumab

Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.

Sponsors
All Listed Sponsors
collaborator

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Beijing Biostar Pharmaceuticals Co., Ltd.

INDUSTRY

lead

Henan Cancer Hospital

OTHER_GOV